• OPEN AN ACCOUNT
A+| A| A-|
Indian Indices
Sensex
78,136.76 949.89
( 1.23%)
Global Indices
Nasdaq
52,569.33 -110.31
(-0.21%)
Dow Jones
7,555.54 -37.86
(-0.50%)
Hang Seng
63,887.74 -2,947.80
(-4.41%)
Nikkei 225
10,555.24 39.32
(0.37%)
Forex
USD-INR
96.26 0.11
(0.12%)
EUR-INR
110.12 0.41
(0.38%)
GBP-INR
129.49 0.88
(0.69%)
JPY-INR
0.59 0.00
(0.14%)

EQUITY - MARKET SCREENER

Aravali Securities & Finance Ltd
Industry :  Finance & Investments
BSE Code
ISIN Demat
Book Value()
512344
INE068C01015
-0.7290145
NSE Symbol
P/E(TTM)
Mar.Cap( Cr.)
ARAVALISEC
0
5.74
EPS(TTM)
Face Value()
Div & Yield %
0
10
0
 

Bafna Pharmaceuticals standalone net profit rises 109.92% in the March 2026 quarter
May 30,2026
Net profit of Bafna Pharmaceuticals rose 109.92% to Rs 2.75 crore in the quarter ended March 2026 as against Rs 1.31 crore during the previous quarter ended March 2025. Sales rose 8.14% to Rs 42.24 crore in the quarter ended March 2026 as against Rs 39.06 crore during the previous quarter ended March 2025.

For the full year,net profit rose 167.47% to Rs 11.10 crore in the year ended March 2026 as against Rs 4.15 crore during the previous year ended March 2025. Sales rose 3.26% to Rs 150.62 crore in the year ended March 2026 as against Rs 145.86 crore during the previous year ended March 2025.

ParticularsQuarter EndedYear Ended
Mar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var.
Sales42.2439.06 8 150.62145.86 3
OPM %8.407.96 -10.587.66 -
PBDT4.283.32 29 17.0411.19 52
PBT2.623.10 -15 10.976.30 74
NP2.751.31 110 11.104.15 167